Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Anal Cancer
•
Medical Oncology
What systemic therapy option do you use for metastatic, anal squamous cancer with progression following FOLFOX and subsequent nivolumab?
Answer from: Medical Oncologist at Academic Institution
If a clinical trial is not available and residual neuropathy from oxaliplatin is not an issue, I would favor carboplatin/paclitaxel.
Sign In
or
Register
to read more
5504
Related Questions
In patients with T1 anal squamous cell cancer status post local excision with a close margin, would you recommend close observation or adjuvant concurrent chemoradiation?
What systemic therapy would you use in patients with gastric cancer who had a relapse after Durva-FLOT (MATTERHORN regimen)?
What patients with new onset diabetes require imaging of the pancreas?
In the setting of total neoadjuvant therapy (TNT) for locally advanced rectal cancer, would you consider using FOLFIRI instead of FOLFOX/CAPOX for consolidative chemotherapy in patients unable to receive oxaliplatin, with the goal of maximizing the chance of clinical complete response and facilitating non-operative management?
How would you approach the management of a patient with stage IIIA lung adenocarcinoma and multifocal hepatocellular carcinoma with Child-Pugh A cirrhosis?
Are you planning to start running IHC HER2 testing on all tumor types, even those where HER2 overexpression is less typical, in light of tumor agnostic approval of trastuzumab deruxtecan?
How, if at all, are you modifying your practice and clinical workflow for patients receiving checkpoint inhibitors with data showing improved outcomes for patients receiving infusions earlier in the day?
After neoadjuvant Nivolumab/Ipilimumab x4, do you offer adjuvant Nivolumab in the adjuvant setting for oligometastatic MSI-high colon cancer in a patient who achieved CR?
When treating rectal cancer with TNT and induction chemotherapy first, do you repeat pelvic MRI prior to planning for chemoradiation?
How does the presence of CNS disease affect your choice of first line therapy in Her2+ gastric adenocarcinoma?